Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 27Fallopian Tube Neoplasms 9Prostatic Neoplasms 8Breast Neoplasms 8Neoplasms 6Pancreatic Neoplasms 5Endometrial Neoplasms 5Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Mesothelioma 3Lung Neoplasms 3Head and Neck Neoplasms 3Glioblastoma 3Carcinoma, Ovarian Epithelial 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Recurrence 2Mesothelioma, Malignant 2Melanoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urogenital Neoplasms 1Thrombocytopenia 1Stomach Neoplasms 1

Interventions

Abiraterone Acetate 5enzalutamide 4abiraterone 3Prednisone 3apalutamide 2Nivolumab 2Docetaxel 2pembrolizumab 1niraparib 1darolutamide 1cabazitaxel 1Pluvicto 1Omeprazole 1Ipilimumab 1Drug Therapy 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Prostatic Neoplasms, Castration-Resistant × niraparib × Clear all
NCT03431350 2026-05-11

QUEST

Janssen Research & Development, LLC

Phase 2 Active not recruiting
136 enrolled 29 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡